IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer's Disease

(marketscreener.com) Company To Host Conference Call on Friday, December 2 at 11 a.m. EThttps://www.marketscreener.com/quote/stock/INDIA-GLOBALIZATION-CAPIT-57355601/news/IGC-Commences-Phase-2-Clinical-Trials-Evaluating-Drug-Candidate-IGC-AD1-for-the-Treatment-of-Agitati-42453715/?utm_medium=RSS&utm_content=20221201